AstraZeneca Shares Hit Two-Month High After $2bn Summit Deal
DailyFX Real Time News 2026-09-29 13:39:41
Context: AstraZeneca has agreed to invest $2 billion in Summit Therapeutics, securing access to the promising cancer drug ivonescimab ahead of a key FDA decision in November. The deal gives AstraZeneca rights equivalent to around 12% of Summit's outstanding common stock and allows the company to combine ivonescimab with its own experimental cancer medicines. This strategic move is part of AstraZeneca's broader oncology strategy, which aims to generate $80 billion in annual revenue by 2030.
Key Facts
- AstraZeneca has agreed to invest $2 billion in Summit Therapeutics, securing rights equivalent to around 12% of Summit's outstanding common stock, or approximately 10.6% on a fully diluted basis.
- The investment gives AstraZeneca access to ivonescimab, a potential first-in-class bispecific antibody that simultaneously targets PD-1 and VEGF, ahead of a key FDA decision on November 14, 2026.
- Ivonescimab is already approved for certain patients with non-small-cell lung cancer in China and has a US application under review by the FDA for combination with chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-squamous non-small-cell lung cancer.
- AstraZeneca's shares climbed to a two-month high at 12,786 pence on Tuesday, September 29, following the announcement of the deal.